From: Multisystem ALK-positive histiocytosis: a multi-case study and literature review
Authors | Gender | Age | Orangs involved | Gene fusion | Treatment | Follow-up |
---|---|---|---|---|---|---|
1. Chang, et al. [2] | M | 2 y 9 mo | CNS, Intestine, hematopoietic system | ALK-FISH +  | Steroids and chemotherapy (ECICM) | DOD (2 mo) |
2. Qiu et al. [12] | M | 49 y | CNS, bone, soft tissue, visceral organs, pleura | KIF5B-ALK | Gamma knife, chemotherapy, and ALK inhibitor | SD (7 mo) |
3. Kashima et al. [5] | F | 16 y | CNS, breast, pancreas, and lungs | KIF5B-ALK | Surgical resection followed by inhibitor | NED (44 mo) |
M | 10 mo | CNS, lung, liver, soft tissue | KIF5B-ALK | Surgical resection followed by chemotherapy (vinblastine/prednisone), combined with ALK inhibitor | NED (13 mo) | |
Kemps et al. [19] | Â | Â | Â | Â | Â | Â |
5. | F | 2 y | CNS, bone, lung, liver, skin, soft tissue, kidney, breast, pancreas, LN | KIF5B-ALK | Chemotherapy (vinblastine/prednisone) followed by ALK inhibitor | ARD (21 mo) |
6. | F | 10 y | CNS, bone, lung, cervix, thyroid, submandibular salivary gland, LN | KIF5B-ALK | ALK inhibitor | NED (2 y) |
7. | F | 19 y | CNS/PNS, bone, lung, liver, breast, pancreas, LN | KIF5B-ALK | Chemotherapy (cladribine), followed by ALK inhibitor | ARD (2 y) |
8. | F | 28 y | CNS/PNS, bone | KIF5B-ALK | ALK inhibitor | ARD (9 mo) |
9. | F | 41 y | CNS, bone, lung, skin, soft tissue, LN | KIF5B-ALK | Interferon-a followed by ALK inhibitor | ARD (6 y) |
Lucas et al. [9] | Â | Â | Â | Â | Â | Â |
10. | F | 7 y | CNS | KIF5B-ALK | Surgical resection | NED (1 y) |
11. | F | 10 y | CNS | KIF5B-ALK | Surgical resection | NED (6 mo) |
F | 11 y | CNS | KIF5B-ALK | Surgical resection | NED (9 mo) | |
Kemps et al. [19] | Â | Â | Â | Â | Â | Â |
13. | F | 7 mo | CNS | KIF5B-ALK | Corticosteroids, followed by ALK inhibitor | ARD (5 mo) |
14. | F | 9 mo | CNS | ALK-FISH +  | N/A | LTF |
15. | M | 2.5 y | CNS | KIF5B-ALK | Chemotherapy followed by ALK inhibitor | NED (16 mo) |
16. | F | 3 y | CNS | KIF5B-ALK | Corticosteroids, followed by surgical resection | NED (12 mo) |
17. | F | 7 y | CNS | KIF5B-ALK | Chemotherapy (clofarabine) | NED (6 mo) |
18. | F | 13 y | CNS/PNS | KIF5B-ALK | Surgical resection followed by ALK inhibitor | ARD (2.5 y) |
19. | M | 20 y | CNS | KIF5B-ALK | Surgical resection | NED (10 mo) |
Current | Â | Â | Â | Â | Â | Â |
20. | F | 51 y | CNS, lung, LN | KIF5B-ALK | Surgical resection followed by ALK inhibitor | ARD (24 mo) |
21. | M | 17 mo | Brain, lung, liver, skin | KIF5B-ALK | Surgical resection followed by chemoradiotherapy and ALK inhibitor | DOD (8 mo) |